Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three drugs—lidocaine, bupivacaine, and fentanyl—used primarily for regional anesthesia and analgesia. Lidocaine and bupivacaine are amide-type local anesthetics that block sodium channels in neuronal membranes, inhibiting nerve impulse conduction to provide local or regional numbness. Fentanyl is a potent synthetic opioid agonist at the mu-opioid receptor, providing strong analgesic effects. The combination leverages the rapid onset of lidocaine, the prolonged duration of bupivacaine, and the synergistic pain relief from fentanyl. This mixture may be used in epidural or spinal anesthesia for surgical procedures or labor analgesia to achieve effective pain control with reduced doses of each component[1][2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + bupivacaine + fentanyl.